BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32627014)

  • 1. Propofol‑induced miR‑125a‑5p inhibits the proliferation and metastasis of ovarian cancer by suppressing LIN28B.
    Zeng J; Li YK; Quan FF; Zeng X; Chen CY; Zeng T; Zou J; Tong WJ
    Mol Med Rep; 2020 Aug; 22(2):1507-1517. PubMed ID: 32627014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
    Sun Y; Peng YB; Ye LL; Ma LX; Zou MY; Cheng ZG
    Mol Med Rep; 2020 Mar; 21(3):1471-1480. PubMed ID: 32016462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propofol suppresses gastric cancer tumorigenesis by modulating the circular RNA‑PVT1/miR‑195‑5p/E26 oncogene homolog 1 axis.
    Sui H; Zhu C; Li Z; Yang J
    Oncol Rep; 2020 Oct; 44(4):1736-1746. PubMed ID: 32945521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propofol inhibits pancreatic cancer proliferation and metastasis by up-regulating miR-328 and down-regulating ADAM8.
    Yu X; Gao Y; Zhang F
    Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):271-278. PubMed ID: 30861616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propofol suppresses cell viability, cell cycle progression and motility and induces cell apoptosis of ovarian cancer cells through suppressing MEK/ERK signaling via targeting circVPS13C/miR-145 axis.
    Lu H; Zheng G; Gao X; Chen C; Zhou M; Zhang L
    J Ovarian Res; 2021 Feb; 14(1):30. PubMed ID: 33563314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA‑125a‑5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1.
    Zha Z; Li J
    Int J Mol Med; 2020 Nov; 46(5):1849-1861. PubMed ID: 33000203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway.
    Zhao Y; Ma K; Yang S; Zhang X; Wang F; Zhang X; Liu H; Fan Q
    Int J Oncol; 2018 Aug; 53(2):644-658. PubMed ID: 29767234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CircNFIX stimulates the proliferation, invasion, and stemness properties of ovarian cancer cells by enhancing SH3RF3 mRNA stability via binding LIN28B.
    Yu XZ; Yang BW; Ao MY; Wu YK; Ye H; Wang RY; Xi MR; Hou MM
    Kaohsiung J Med Sci; 2023 Mar; 39(3):234-243. PubMed ID: 36495291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR‑125a‑5p reverses epithelial‑mesenchymal transition and restores drug sensitivity by negatively regulating TAFAZZIN signaling in breast cancer.
    Li D; Chen L; Zhang X; Wang Y; Huang C; Li J; He F; He W
    Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34549308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propofol inhibits invasion and growth of ovarian cancer cells via regulating miR-9/NF-κB signal.
    Huang X; Teng Y; Yang H; Ma J
    Braz J Med Biol Res; 2016 Dec; 49(12):e5717. PubMed ID: 27982283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA‑125a‑5p controls the proliferation, apoptosis, migration and PTEN/MEK1/2/ERK1/2 signaling pathway in MCF‑7 breast cancer cells.
    Liang Z; Pan Q; Zhang Z; Huang C; Yan Z; Zhang Y; Li J
    Mol Med Rep; 2019 Nov; 20(5):4507-4514. PubMed ID: 31702027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer.
    Yang Y; Wei Q; Tang Y; Yuanyuan Wang ; Luo Q; Zhao H; He M; Wang H; Zeng Q; Lu W; Xu J; Liu T; Yi P
    Cancer Lett; 2020 Apr; 475():43-52. PubMed ID: 32006618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaphorin 3A inhibits tumor progression via the downregulation of Lin28B in ovarian cancer.
    Ma RY; Yang LN; Chen JN; Chen RJ; Zhang LW; Wang XQ
    Neoplasma; 2023 Feb; 70(1):103-113. PubMed ID: 36660796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal lncRNA H19 promotes the progression of hepatocellular carcinoma treated with Propofol via miR-520a-3p/LIMK1 axis.
    Wang D; Xing N; Yang T; Liu J; Zhao H; He J; Ai Y; Yang J
    Cancer Med; 2020 Oct; 9(19):7218-7230. PubMed ID: 32767662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent treatment with simvastatin and NF-κB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-κB/LIN28/let-7 miRNA signaling pathway.
    Kang M; Lee KH; Lee HS; Jeong CW; Ku JH; Kim HH; Kwak C
    PLoS One; 2017; 12(9):e0184644. PubMed ID: 28910332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung but not brain cancer cell malignancy inhibited by commonly used anesthetic propofol during surgery: Implication of reducing cancer recurrence risk.
    Hu C; Iwasaki M; Liu Z; Wang B; Li X; Lin H; Li J; Li JV; Lian Q; Ma D
    J Adv Res; 2021 Jul; 31():1-12. PubMed ID: 34194828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The upregulation of TMPRSS4, partly ascribed to the downregulation of miR‑125a‑5p, promotes the growth of human lung adenocarcinoma via the NF‑κB signaling pathway.
    Fan X; Liang Y; Liu Y; Bai Y; Yang C; Xu S
    Int J Oncol; 2018 Jul; 53(1):148-158. PubMed ID: 29750426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
    Huang J; Cao D; Sha J; Zhu X; Han S
    Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1.
    Zhang XL; Sun BL; Tian SX; Li L; Zhao YC; Shi PP
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3635-3644. PubMed ID: 31114988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.